Note: Descriptions are shown in the official language in which they were submitted.
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
USE OF AN mTOR INHIBITOR IN TREATMENT OF UTERINE
LEIOMYOMA
BACKGROUND OF THE INVENTION
This invention relates to the use of an mTOR inhibitor in the treatment or
inhibition of uterine leiomyoma (fibroids) in a mammal.
mTOR, also known as FKBP12-rapamycin associated protein (FRAP), is a key
enzyme in a variety of signal transduction pathways, including cytokine-
stimulated cell
proliferation, translation of mRNAs for several key proteins that regulate the
Gl phase of
the cell cycle, and interleukin-2 (IL-2) induced transcription. Inhibition of
mTOR leads
to the inhibition of the progression of the cell cycle from Gl to S. Rapamycin
(commercially available as SirolimusTM), a macrocycline triene antibiotic
produced by
Streptomyces hygroscopicus, has been identified as a key mTOR inhibitor.
Rapamycin 42-ester with 3-hydroxy-2-(hydroxyinethyl)-2-methylpropionic acid
(CCI-779) is an ester of rapamycin. The preparation and use of hydroxyesters
of
rapamycin, including CCI-779, are described in U.S. Patent Nos. 5,362,718 and
6,277,983. Still another regioselective method for synthesis of CCI-779 is
described in
U.S. Patent Application No. 10/903,062, filed July 30, 2004 (published
February 10, 2005
as U.S. Patent Publication No. US 2005-0033046 Al), and its counterpart,
International
Patent Application No. PCT/US2004/22860 (published February 24, 2005 as
International Patent Publication No. WO 2005/016935 A3). CCI-779 has been
described
as having an in vitro and in vivo activity against a number of tumor cell
types. CCI-779
binds to and forms a complex with the cytoplasmic protein FKBP, which inhibits
mTOR.
It is hypothesized that CCI-779 delays the time to progression of tumors or
time to tumor
recurrence. This mechanism of action is more typical of cytostatic rather than
cytotoxic
agents and is similar to that of sirolimus.
Uterine leiomyoma (fibroids) are benign tumors arising from the myometrium
(smooth muscle layer) of the uterus. Leiomyoma are the most common solid
pelvic
tumor of women and are 2-5 times more likely to occur in black women than
white
women. Fibroids occur in as many as 75% of reproductive age women, with 25% of
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
these women symptomatic to the point of seeking treatment. Women with
symptomatic
fibroids suffer from menorrhagia, pelvic pain and pressure, and are more
subject to
reproductive dysfunction such as infertility or multiple miscarriages.
The primary treatment for patients with fibroids is surgery - either
myomectomy
for removal of tumor and preservation of childbearing potential, or
hysterectomy.
Fibroids are the most common indication for hysterectomy and account for
approximately
200,000 procedures performed annually in the United States.
Thus, there is a need in the art for more effective methods of treating and
inhibiting fibroids.
SUMMARY OF THE INVENTION
The invention provides for the use of an mTOR inhibitor in treating or
inhibiting,
or in the preparation of a medicament useful in treating or inhibiting,
uterine leiomyoma
(fibroids) in a female mammalian subject. In another aspect, the invention
provides for
the use of a rapamycin in treating or inhibiting, or in the preparation of a
medicament
useful in treating or inhibiting, uterine leiomyoma in a female mammalian
subject. In one
embodiment, the invention provides the use of rapamycin or CCI-779 in treating
or
inhibiting, or in the preparation of a medicament useful in treating or
inhibiting, uterine
leiomyoma in a female mammalian subject.
In other aspects, the invention provides for pharmaceutical compositions
comprising an mTOR inhibitor, and in certain embodiments, a rapamycin,
rapamycin, or
CCI-779, in unit dosage form in association with a pharmaceutically acceptable
carrier,
which are useful in treating or inhibiting uterine leiomyoma in a female
mammalian
subj ect.
In yet another embodiment, the invention provides for pharmaceutical packs
containing a course of treatment of uterine leiomyoma for one individual
mammal, each
pack comprising a container having one unit, one to four units, or more units
of an mTOR
inhibitor, and in certain embodiments, a rapamycin, rapamycin or CCI-779 in
unit dosage
fonn.
Other aspects and advantages of the invention will be apparent from the
following
detailed description of the invention.
2
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides methods of using an effective amount of an mTOR
inhibitor in the treatment or inhibition of, or in the preparation of a
medicament useful in
treating or inhibiting, uterine leiomyoma (fibroids). In one embodiment, an
effective
amount of rapamycin is useful in methods of treating or inhibiting fibroids.
In another
embodiment, an effective amount of CCI-779 (rapamycin 42-ester with 3-hydroxy-
2-
(hydroxymethyl)-2-methylpropionic acid) is useful in methods of treating or
inhibiting
fibroids. Other compounds useful in the methods of the invention in treating
or inhibiting
fibroids include effective amounts of a rapamycin, such as esters (including
42-esters),
ethers (including 42-ethers), oximes, hydrazones, and hydroxylamines of
rapamycin. In
another embodiment, the invention provides for methods of treating or
inhibiting fibroids
using an effective amount of 42-0-(2-hydroxy)ethyl rapamycin (CerticanTm
(everolimus)).
In another embodiment, FK-506 is useful in methods of treating or inhibiting
fibroids. In another embodiment, AP23573 is useful in methods of treating or
inhibiting
fibroids.
As used herein, the term fibroid or fibroids shall have the same meaning as
uterine leiomyoma, as described above.
As used herein, the term mTOR inhibitor means a compound or ligand, or a
pharmaceutically acceptable salt thereof, that inhibits cell replication by
blocking the
progression of the cell cycle from G1 to S. The term includes the neutral
tricyclic
compound rapamycin (sirolimus) and other rapamycin compounds, including, e.g.,
rapamycin derivatives, rapamycin analogues, other macrolide compounds that
inhibit
mTOR activity, and all compounds included within the definition below of the
term "a
rapamycin".
These include compounds with a structural similarity to "a rapamycin", e.g.,
compounds with a similar macrocyclic structure that have been modified to
enhance
therapeutic benefit. The term also includes, e.g., rapamycin, 32-
deoxorapamycin, 16-
pent-2-ynyloxy-32-deoxorapamycin, 16-pent-2-ylyloxy-32(S)-dihydro-rapamycin,
16-
pent-2-ylyloxy-32(S)-dihydr-o-40-O-(2-hydroxyethyl)-rapamycin, 40-0-(2-
hydroxyethyl)-rapamycin, rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-
3
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
methylpropionic acid (CCI-779), 40-[3-hydroxy-2-(hydroxymethyl)-2-meth-
ylpropanoate]-rapamycin, or a pharmaceutically acceptable salt thereof, as
disclosed in
U.S. Patent No. 5,362,718, ABT578, or 40-(tetrazolyl)-rapamycin, 40-epi-
(tetrazolyl)-
rapamycin, e.g., as disclosed in International Patent Publication No. WO
99/15530, or
rapamycin analogs as disclosed in International Patent Publication No. WO
98/02441 and
WO 01/14387, e.g., AP23573.
FK-506 can also be used in the method of the invention.
As used herein, the term a rapamycin defines a class of immunosuppressive
compounds that contain the basic rapamycin nucleus as shown below.
OH
42
-OMe
N 0 0 OH
31
HO 0 O Me0"
0 OMe
=
The rapamycins of this invention include compounds that are chemically or
biologically
modified as derivatives of the rapamycin nucleus, while still retaining
immunosuppressive properties. Accordingly, the term a rapamycin includes
rapamycin,
and esters, ethers, carbamates, oximes, hydrazones, and hydroxylamines of
rapamycin, as
well as rapamycins in which functional groups on the rapamycin nucleus have
been
modified, for example through reduction or oxidation. Also included in the
term a
rapamycin are pharmaceutically acceptable salts of rapamycins.
The term a rapamycin also includes 42- and/or 31-esters and ethers of
rapamycin
as described in the following patents, which are all hereby incorporated by
reference:
alkyl esters (U.S. Patent No. 4,316,885); aminoalkyl esters (U.S. Patent No.
4,650,803);
fluorinated esters (U.S. Patent No. 5,100,883); amide esters (U.S. Patent No.
5,118,677);
carbamate esters (U.S. Patent No. 5,118, 678); silyl esters (U.S. Patent No.
5,120,842);
aminodiesters (U.S. Patent No. 5,162,333); sulfonate and sulfate esters (U.S.
Patent No.
5,177,203); esters (U.S. Patent No. 5,221,670); alkoxyesters (U.S. Patent No.
5,233,036);
4
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
0-aryl, -alkyl, -alkenyl, and -alkynyl ethers (U.S. Patent No. 5,258,389);
carbonate esters
(U.S. Patent No. 5,260,300); arylcarbonyl and alkoxycarbonyl carbamates (U.S.
Patent
No. 5,262,423); carbamates (U.S. Patent No. 5,302,584); hydroxyesters (U.S.
Patent No.
5,362,718); hindered esters (U.S. Patent No. 5,385,908); heterocyclic esters
(U.S. Patent
No. 5,385,909); gem-disubstituted esters (U.S. Patent No. 5,385,910); amino
alkanoic
esters (U.S. Patent No. 5,389,639); phosphorylcarbamate esters (U.S. Patent
No.
5,391,730); carbamate esters (U.S. Patent No. 5,411,967); carbamate esters
(U.S. Patent
No. 5,434,260); amidino carbamate esters (U.S. Patent No. 5,463,048);
carbamate esters
(U.S. Patent No. 5,480,988); carbamate esters (U.S. Patent No. 5,480,989);
carbamate
esters (U.S. Patent No. 5,489,680); hindered N-oxide esters (U.S. Patent No.
5,491,231);
biotin esters (U.S. Patent No. 5,504,091); 0-alkyl ethers (U.S. Patent No.
5,665,772); and
PEG esters of rapamycin (U.S. Patent No. 5,780,462). The preparation of these
esters and
ethers is disclosed in the patents listed above.
Further included within the definition of the term a rapamycin are 27-esters
and
ethers of rapamycin, which are disclosed in U.S. Patent No. 5,256,790, which
is hereby
incorporated by reference. Also described are C-27 ketone rapamycins which are
reduced
to the corresponding alcohol, which is in turn converted to the corresponding
ester or
ether. The preparation of these esters and ethers is disclosed in the patent
listed above.
Also included are oximes, hydrazones, and hydroxylamines of rapamycin are
disclosed in
U.S. Patent Nos. 5,373,014, 5,378,836, 5,023,264, and 5,563,145, which are
hereby
incorporated by reference. The preparation of these oximes, hydrazones, and
hydroxylamines is disclosed in the above-listed patents. The preparation of 42-
oxorapamycin is disclosed in 5,023,263, which is hereby incorporated by
reference.
As used herein, the term a CCI-779 means rapamycin 42-ester with 3-hydroxy-2-
(hydroxymethyl)-2-methylpropionic acid, and encompasses prodrugs, derivatives,
pharmaceutically acceptable salts, or analogs thereof.
As used herein, the term treatment means treating a mammal having fibroids
(uterine leiomyoma) by providing said mammal with an effective amount of a
compound
or composition for the purpose of inhibiting growth of the fibroid,
eradication of the
fibroid, or palliation of the fibroid.
5
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
As used herein, the term inhibition means delaying or preventing the onset or
progression of fibroids in a mammal having or susceptible to developing such
disease by
providing said mammal with an effective amount of a compound or composition of
the
invention.
As used herein, the term providing means either directly administering a
compound or composition of the invention or administering a prodrug,
derivative,
pharmaceutical salt, or analog of an mTOR inhibitor, which will result in a
desired
ainount of the compound or composition in the body.
All terms used herein, whether used in the singular or plural form, shall
include
both the singular and plural form unless otherwise indicated.
As used herein, the terms include, includes, and including indicates that the
subject is open to other items, i.e., an open class.
As used herein, the terms comprise, comprises, and comprising indicates that
the
subject is open to other items, i.e., an open class.
As used herein, the terms contain, contains, and containing indicates that the
subject is open to other items, i.e., an open class.
As used herein, the terms consists of and consisting of indicates that the
subject is
closed to other items, i.e., a closed class.
All other terms used herein shall be defined as expressly or impliedly defined
within this specification, and then, if necessary, in accordance with their
interpretation by
one of ordinary skill in the relevant art.
Compositions/Formulations:
Compositions useful in the present invention comprise an active compound
(e.g,,
an mTOR inhibitor) as described herein. In one einbodiment, the compound is
CCI-779
(rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic
acid)(U.S.
Patent No. 5,362,718). The preparation of CCI-779 is disclosed in U.S. Patent
No.
5,362,718, which is hereby incorporated by reference. A regioselective
preparation of
CCI-779 is described in U.S. Patent No. 6,277,983. Still another regiospecific
method for
synthesis of CCI-779 is described in US Patent Application No. 10/903,062,
filed July 30,
6
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
2004, and its counterpart, International Patent Application PCT/US2004/22860,
filed July
15, 2004. Rapamycin is commercially available as Sirolimus'FM.
In another embodiment, the compound is AP23573. In another embodiment, the
compound is CerticanTm (everolimus). Other compounds useful in the methods,
compositions, and pharmaceutical packs of the invention include a rapamycin,
such as
rapamycin, esters (including 42-esters), ethers (including 42-ethers), oximes,
hydrazones,
and hydroxylamines of rapamycin. In another embodiment, the raparnycin is 42-0-
(2-
hydroxy)ethyl rapamycin (everolimus, Novartis, U.S. Patent No. 5,665,772,
hereby
incorporated by reference). In other embodiments, compositions of the present
invention
contain other compounds useful in the invention as described herein.
In yet another embodiment, the compound is FK-506.
Administration of the compositions maybe oral, intravenous, respiratory (e.g.,
nasal or intrabronchial), parenteral, intraperitoneal, transdermal (including
all
administration across the surface of the body and the inner linings of bodily
passages
including epithelial and mucosal tissues), and vaginal (including intrauterine
administration).
It is projected that the oral dosage of a compound useful in the invention
will be
10 mg/ week to 250 mg/week, about 20 mg/week to about 150 mg/week, about 25
mg/week to about 100 mg/week, or about 30 mg/week to about 75 mg/week. For
rapamycin, the projected oral dosage will be between 0.1 mg/day to 25 mg/day.
Intravenous dosages are generally predicted to be five to tenfold less than
oral dosages.
Precise dosages will be determined by the administering physician based on
experience
with the individual subject to be treated.
In one enlbodiment, the pharmaceutical composition is in unit dosage form,
e.g.,
as tablets, capsules, or pre-filled vials or syringes. In such form, the
composition is sub-
divided in unit dose containing appropriate quantities of the active
ingredient; the unit
dosage forms can be packaged compositions, for example, packeted powders,
vials,
ampoules, pre-filled syringes or sachets containing liquids. The unit dosage
form can be,
for example, a capsule or tablet itself, or it can be the appropriate number
of any such
compositions in package form.
7
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
Oral formulations containing the compounds of this invention may comprise any
conventionally used forms, including tablets, capsules, buccal forms, troches,
lozenges
and oral liquids, suspensions or solutions. Capsules may contain mixtures of
the active
compound(s) with inert fillers and/or diluents such as pharmaceutically
acceptable
starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening
agents,
powdered celluloses, such as crystalline and microcrystalline celluloses,
flours, gelatins,
gums, etc. Useful tablet formulations may be made by conventional compression,
wet
granulation or dry granulation methods and utilize pharmaceutically acceptable
diluents,
binding agents, lubricants, disintegrants, surface modifying agents (including
surfactants),
suspending or stabilizing agents, including, but not limited to, magnesium
stearate, stearic
acid, talc, sodium laurel sulfate, microcrystalline cellulose,
carboxymethylcellulose
calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xantham gum,
sodium
citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose,
sorbitol, dicalcium
phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, dry
starches and
powdered sugar. Surface modifying agents include nonionic and anionic surface
modifying agents. Representative examples of surface modifying agents include,
but are
not limited to, poloxamer 188, benzalkonium chloride, calcium stearate,
cetostearyl
alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon
dioxide,
phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and
triethanolamine.
Oral formulations herein may utilize delay or time release formulations to
alter the
absorption of the active compound(s). The oral formulation may also comprise
administering the active compound in water or a fruit juice, containing
appropriate
solubilizers or emulsifiers as needed. Preferred oral formulations for CCI-779
are
disclosed in U.S. Published Patent Application No. US 2004-0077677 Al (also
U.S.
Patent Application No. 10/663,506). Preferred solid oral formulations for
rapamycin are
disclosed in US Patent 5,989,591, and preferred oral liquid formulations for
rapamycin
are disclosed in 5,536,729.
In some cases it may be desirable to administer the compounds directly to the
airways in the form of an aerosol.
The compounds may also be administered parenterally or intraperitoneally.
Solutions or suspensions of these active compounds as a free base or
pharmacologically
8
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
acceptable salt can be prepared in water suitably mixed with a surfactant such
as hydroxy-
propylcellulose. Dispersions can also be prepared in glycerol, liquid
polyethylene glycols
and mixtures thereof in oils. Under ordinary conditions of storage and use,
these
preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous
solutions or dispersions and sterile powders for the extemporaneous
preparation of sterile
injectable solutions or dispersions. In all cases, the form must be sterile
and must be fluid
to the extent that easy syringability exists. It must be stable under the
conditions of
manufacture and storage and must be preserved against the contaminating action
of
microorganisms such as bacteria and fungi. The carrier can be a solvent or
dispersion
medium containing, for example, water, ethanol, polyol (e.g., glycerol,
propylene glycol,
and liquid polyethylene glycol), suitable mixtures thereof, and vegetable
oils. In one
embodiment, injectable formulations for CCI-779 are disclosed in U.S. Patent
Publication
No. US 2004-0167152 (also U.S. Patent Application No. 10/626,943), which is
hereby
incorporated by reference.
In one embodiment, the injectable formulation useful in the invention provides
a
compound in a cosolvent concentrate containing a parenterally acceptable
solvent and an
antioxidant as described above and a parenteral fonnulation containing a
compound
useful in the invention, a parenterally acceptable cosolvent, an antioxidant,
a diluent
solvent, and a surfactant. Any given formulation useful in this invention may
contain
multiple ingredients of each class of component. For example, a parenterally
acceptable
solvent can include a nonalcoholic solvent, an alcoholic solvent, or mixtures
thereof.
Examples of suitable non-alcoholic solvents include, e.g., dimethylacetamide,
dimethylsulfoxide or acetonitrile, or mixtures thereof. An alcoholic solvent
may contain
one or more alcohols as the alcoholic solvent component of the formulation.
Examples of
solvents useful in the formulations of the invention include, without
limitation, ethanol,
propylene glycol, polyethylene glyco1300, polyethylene glyco1400, polyethylene
glycol
600, polyethylene glycol 1000, or mixtures thereof. These cosolvents are
particularly
desirable because degradation via oxidation and lactone cleavage occurs to a
lower extent
for these cosolvents. Further, ethanol and propylene glycol can be combined to
produce a
less flammable product, but larger amounts of ethanol in the mixture generally
result in
9
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
better chemical stability. A concentration of 30 to 100% v/v ethanol in the
mixture is
preferred.
In another embodiment, the stability of a compound useful in the invention in
parenterally acceptable alcoholic solvents is enhanced by addition of an
antioxidant to the
formulation. Acceptable antioxidants include, but are not limited to, citric
acid, d,1-a-
tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, propyl gallate, and
mixtures
thereof. Generally, the parenteral formulations useful in this embodiment will
contain an
antioxidant component(s) in a concentration ranging from 0.001 % to 1% w/v, or
0.01% to
0.5% w/v, of the cosolvent concentrate although lower or higher concentrations
may be
desired. In one embodiment, of the antioxidants, d,1-a-tocopherol is
particularly
desirable and is used at a concentration of 0.01 to 0.1 % w/v with a preferred
concentration of 0.075% w/v of the cosolvent concentrate.
In other embodiments, the antioxidant component of the formulation of the
invention also exhibits chelating activity. Examples of such chelating agents
include,
e.g., citric acid, acetic acid, and ascorbic acid (which may function as both
a classic
antioxidant and a chelating agent in the present formulations). Other
chelating agents
include such materials as are capable of binding metal ions in solution, such
as ethylene
diamine tetra acetic acid (EDTA), its salts, or amino acids such as glycine
are capable of
enhancing the stability of a compound useful in the invention. In some
embodiments,
components with chelating activity are included in the formulations of the
invention as
the sole antioxidant component. Typically, such metal-binding components, when
acting
as chelating agents are used in the lower end of the range of concentrations
for the
antioxidant components provided herein. Higher concentrations yield less
stable
solutions and thus, less desirable for products to be subject to long-term
storage in liquid
form. Additionally, such chelating agents may be used in combination with
other
antioxidants as part of the antioxidant component of the invention. For
example, an
acceptable formulation may contain both citric acid and d,l-a-tocopherol.
Optimal
concentrations for the selected antioxidant(s) can be readily determined by
one of
ordinary skill in the art, based upon the information provided herein.
In certain embodiments of the parenteral formulations useful in the invention,
surfactants are used in the diluent solution to prevent precipitation of the
components of
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
the formulation. Parenterally acceptable surfactants may be readily selected
by one of
ordinary skill in the art and include: polysorbate 20, polysorbate 80, salts
of bile acids
(taurocholate, glycocholate, cholate, deoxycholate, etc.), which are
optionally combined
with lecithin. Alternatively, ethoxylated vegetable oils, such as a pegylated
castor oil
(e.g., such as PEG-35 castor oil which is sold, e.g., under the name Cremophor
EL,
BASF), vitamin E tocopherol propylene glycol succinate (Vitamin E TGPS), and
polyoxyethylene-polyoxypropylene block copolymers can be used in the diluent
as a
surfactant, as well as other members of the polysorbate family such as
polysorbate 20 or
60. Other components of the diluent may include water, ethanol, polyethylene
glycol
300, polyethylene glyco1400, polyethylene glyco1600, polyethylene glycol 1000,
or
blends containing one or more of these polyethylene glycols, propylene glycol
and other
parenterally acceptable sugars, polyols and electrolytes. It is expected that
the surfactant
will comprise 2 to 100% w/v, 5 to 80% w/v, 10 to 75% w/v, 15 to 60% w/v, 5%
w/v, or
10% w/v, of the diluent solution.
A parenteral formulation useful in the invention can be prepared as a single
solution, or can be prepared as a cosolvent concentrate containing a compound
useful in
the invention, an alcoholic solvent, and an antioxidant, which is subsequently
combined
with a diluent that contains a diluent solvent and suitable surfactant. Prior
to use, the
cosolvent concentrate is mixed with a diluent comprising a diluent solvent,
and a
surfactant. In one embodiment, a compound useful in the invention is prepared
as a
cosolvent concentrate according to the invention, having concentrations of
compound
from 0.05 mg/mL, from 2.5 mg/mL, from 5 mg/mL, from 10 mg/mL, or from 25 mg/mL
up to approximately 50 mg/mL. The concentrate can be mixed with the diluent up
to
approximately 25 mg/mL. For example, the concentration of a compound useful in
the
invention in the parenteral formulation may be from about 2.5 to 10 mg/mL.
This
invention also covers the use of formulations having lesser concentrations of
a compound
useful in the invention in the cosolvent concentrate, and formulations in
which one part of
the concentrate is mixed with greater than 1 part of the diluent, e.g.,
concentrate:diluent in
a ratio of about 1:1.5, 1:2, 1:3, 1:4, 1:5, or 1:9 v/v, and so on, to
parenteral formulations
having compound concentrations down to the lowest levels of detection.
11
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
In another embodiment, the antioxidant may comprise from about 0.0005 to 0.5%
w/v of the formulation. The surfactant may, for example, comprise from about
0.5% to
about 10% w/v of the formulation. The alcoholic solvent may be, for example,
from
about 10% to about 90% w/v of the formulation.
In other embodiments, the parenteral formulations useful in this invention can
be
used to produce a dosage form that is suitable for administration by either
direct injection
or by addition to sterile infusion fluids for intravenous infusion.
Transdermal administration may be accomplished through the use of a
transdermal patch containing the active compound and a carrier that is inert
to the active
compound, is non-toxic to the skin, and allows delivery of the agent for
systemic
absorption into the blood stream via the skin. Such administrations may be
carried out
using the compounds useful in the invention, or pharmaceutically acceptable
salts thereof,
in lotions, creams, foams, patches, suspensions, solutions, and suppositories
(rectal and
vaginal). The carrier may take any number of forms such as creams and
ointments,
pastes, gels, and occlusive devices. The creams and ointments may be viscous
liquid or
semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes
comprised of
absorptive powders dispersed in petroleum or hydrophilic petroleum containing
the active
ingredient into the blood stream such as a semi-permeable membrane covering a
reservoir
containing the active compound into the blood stream such as a semi-permeable
membrane covering a reservoir containing the active compound with or without a
carrier,
or a matrix containing the active compound. Other occlusive devices are known
in the
literature and would be readily available to one of skill in the art.
Suppository formulations may be made from traditional materials, including
cocoa
butter, with or without the addition of waxes to alter the suppository's
melting point, and
glycerin. Water soluble suppository bases, such as polyethylene glycols of
various
molecular weights, may also be used.
In one embodiment, the compositions are delivered vaginally in the form of a
conventional suppository, cream, gel, ring, or coated intrauterine device
(IUD).
12
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
Pharmaceutical Packs/Kits:
The invention includes a product or pharmaceutical pack containing a course of
treatment of uterine leiomyoma for one individual mammal comprising one or
more
container(s) having one, one to four, or more unit(s) of an mTOR inhibitor
(e.g., CCI-
779) in unit dosage form
In another embodiment, pharmaceutical packs contain a course of treatment of
uterine leiomyoma for one individual mammal comprising a container having a
unit of a
rapamycin in unit dosage form. In other embodiments, the rapamycin is
rapamycin, an
ester (including a 42-ester, ether (including a 42-ether), oxime, hydrazone,
or
hydroxylamine of rapamycin. In another embodiment, the rapamycin is 42-0-(2-
hydroxy)ethyl rapamycin.
In another embodiment, the rapamycin is CCI-779, and the pack contains one or
more container(s) comprising one, one to four, or more unit(s) of CCI-779.
In some embodiments, the compositions of the invention are in packs in a form
ready for administration. In other embodiments, the compositions of the
invention are in
concentrated form in packs, optionally with the diluent required to make a
final solution
for administration. In still other embodiments, the product contains a
compound useful in
the invention in solid form and, optionally, a separate container with a
suitable solvent or
carrier for the compound useful in the invention.
In still other embodiments, the above packs/kits include other components,
e.g.,
instructions for dilution, mixing and/or administration of the product, other
containers,
syringes, needles, etc. Other such pack/kit components will be readily
apparent to one of
skill in the art.
The following examples are illustrative of the present invention, but are not
a
limitation thereof.
13
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
EXAMPLES
Example 1: In vivo testing of the effectiveness of treatment of fibroids in
the Eker
rat
A. Background:
The Eker rat is a well-characterized model system for uterine leiomyoma
[Walker, et al., Genes, Chromosomes, and Cancer, 38:349-356 (2003); Houston,
et al.,
Cancer Research, 63:1221-1227 (2003); and Walker, C.L., Jounnal of the Society
for
Gynecologic Investigation, 7(4), 249-256 (2000)]. Approximately 65% of virgin
female
Eker rats spontaneously develop uterine leiomyoma by 12-16 months as a result
of
mutation of the Tsc-2 gene.
B. Method:
Eker rats 12-16 months of age are treated with a compound useful in the
invention and evaluated for tumor regression via conventional techniques and
methods
(e.g., ultrasound or laparascopy). RNA/protein obtained from study animals is
obtained
and used in vitro for characterization of the mechanism(s) of compound
effectiveness.
C. Results:
A tested mTOR inhibitor, e.g., CCI-779, is expected to be effective in the
treatment of uterine leiomyoma (fibroids) in the dosage range of approximately
10-250
mg/week (oral) or approximately 2-50 mg/week (intravenous). A tested rapamycin
is
expected to be effective at the projected oral dosage of between 0.1 mg/day to
25 mg/day.
Example 2: In vivo testing of the effectiveness of treatment of fibroids in
the
Guinea pig
A. Background:
Guinea pigs spontaneously develop fibroids as they age. This process may
be accelerated by administration of estradiol, all-trans retinoic acid and
troglitazone
[Tsibris, et al., J. Soc. Gynecol. Invest., 5(suppll):180 (abstract)(1998);
Tsibris, et al.,
Cancer Res., 59:5737 (1999); and U.S. Patent No. 6,218,594 B1].
14
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
B. Method:
Fibroids are induced in Guinea pigs by treatment with estradiol, all-trans
retinoic acid and troglitazone. Guinea pigs are then treated with a compound
useful in the
invention and evaluated for tumor regression via conventional techniques and
methods
(e.g., ultrasound or laparascopy). RNA/protein obtained from study animals is
obtained
and used in vitro for characterization of the mechanism(s) of compound
effectiveness.
C. Results:
A tested mTOR inhibitor, e.g., CCI-779, is expected to be effective in the
treatment of uterine leiomyoma (fibroids) in the dosage range of approximately
10-250
ing/week (oral) or approximately 2-50 mg/week (intravenous). A tested
rapamycin is
expected to be effective at the projected oral dosage of between 0.1 mg/day to
25 mg/day.
Example 3: In vivo testing of the effectiveness of inhibition of fibroids in
the Eker
rat
A. Background:
The Eker rat is a well-characterized model system for uterine leiomyoma
[Walker, et al., Genes, Chronzosomes, and CanceY, 38:349-356 (2003); Houston,
et al.,
Cancer Research, 63:1221-1227 (2003); and Walker, C.L., Journal of the Society
for
Gynecologic Investigation, 7(4), 249-256 (2000)]. Approximately 65% of virgin
female
Eker rats spontaneously develop uterine leiomyoma by 12-16 months as a result
of
mutation of the Tsc-2 gene.
B. Method:
Eker rats at approximately 9 months of age are treated with a compound
useful in the invention and evaluated for tumor inhibition by comparison with
a vehicle-
treated control group until following the time in which vehicle-treated rats
have
developed tumors (about 12-16 months of age). Tumor growth is monitored via
conventional techniques and methods (e.g., ultrasound or laparoscopy).
RNA/protein
obtained from study animals is obtained and used for characterization of
compound
effectiveness.
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
C. Results:
A tested mTOR inhibitor, e.g., CCI-779, is expected to be effective in the
inhibition of uterine leiomyoma (fibroids) in the dosage range of
approximately 10-250
mg/week (oral) or approximately 2-50 mg/week (intravenous). A tested
rapanlycin is
expected to be effective at the projected oral dosage of between 0.1 mg/day to
25 mg/day.
Example 4: In vivo testing of the effectiveness of inhibition of fibroids in
the
Guinea pig
A. Background:
Guinea pigs spontaneously develop fibroids as they age. This process may
be accelerated by administration of estradiol, all-trans retinoic acid and
troglitazone
[Tsibris, et al., J. Soc. Gynecol. Invest., 5(suppll):180 (abstract)(1998);
Tsibris, et al.,
Cancer Res., 59:5737 (1999); and U.S. Patent No. 6,218,594 B1].
B. Method:
Healthy Guinea pigs, not having fibroids, are treated with a compound
useful in the invention and evaluated for tumor regression via conventional
techniques
and methods (e.g., ultrasound or laparascopy). Guinea pigs are then subjected
to
treatment with estradiol, all-trans retinoic acid and troglitazone, and
compared to Guinea
pigs not pre-treated with a compound useful in the invention. RNA/protein
obtained from
study animals is obtained and used in vitro for characterization of the
mechanism(s)
involved in fibroid tumorigenesis.
C. Results:
A tested mTOR inhibitor, e.g., CCI-779, is expected to be effective in the
inhibition of uterine leiomyoma (fibroids) in the dosage range of
approximately 10-250
mg/week (oral) or approximately 2-50 mg/week (intravenous). A tested rapamycin
is
expected to be effective at the projected oral dosage of between 0.1 mg/day to
25 mg/day.
16
CA 02585840 2007-04-26
WO 2006/050461 PCT/US2005/039836
All documents identified herein are incorporated by reference. One of skill in
the
art will recognize that minor modifications to the conditions and techniques
described in
the specific embodiments described herein can be varied without departing from
the
present invention. Such minor modifications and variants are within the scope
of the
invention as defined by the following claims.
17
